Citius Pharmaceuticals (NASDAQ:CTXR – Get Free Report) is projected to issue its Q4 2025 results before the market opens on Friday, December 26th. Analysts expect the company to announce earnings of ($0.24) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Monday, December 29, 2025 at 4:00 PM ET.
Citius Pharmaceuticals Price Performance
CTXR stock opened at $1.02 on Friday. Citius Pharmaceuticals has a 1 year low of $0.65 and a 1 year high of $5.95. The company has a market cap of $17.35 million, a P/E ratio of -0.30 and a beta of 1.51. The stock’s fifty day moving average price is $1.30 and its 200-day moving average price is $1.31.
Wall Street Analyst Weigh In
A number of analysts have commented on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Citius Pharmaceuticals in a report on Monday. Wall Street Zen lowered Citius Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Friday, September 26th. Finally, D. Boral Capital reissued a “buy” rating and set a $6.00 price objective on shares of Citius Pharmaceuticals in a report on Thursday, December 4th. One investment analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $6.00.
Institutional Trading of Citius Pharmaceuticals
An institutional investor recently bought a new position in Citius Pharmaceuticals stock. NewEdge Advisors LLC bought a new stake in shares of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR – Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 25,000 shares of the company’s stock, valued at approximately $40,000. NewEdge Advisors LLC owned approximately 0.24% of Citius Pharmaceuticals at the end of the most recent reporting period. 16.88% of the stock is owned by institutional investors.
About Citius Pharmaceuticals
Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.
Recommended Stories
- Five stocks we like better than Citius Pharmaceuticals
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Broadcom Stock Crashes 20%—But Wall Street Sees It Soaring to $500
- Value Investing: Is it a Good Strategy in 2022? (Hint: Always)
- Forget the Chips: 4 Industrial Plays for the AI Rebound
- Quiet Period Expirations Explained
- MongoDB Could Hit Record Highs—But You’ll Need to Move Fast
Receive News & Ratings for Citius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Citius Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
